Criteria for Preservative Free (PF) and Single Dose Unit (SDU) presentations:
These are restricted to patients with • true preservative allergy and/or • evidence of epithelial toxicity from preservatives and/or • severe dry eyes and/or • require/ may require surgery in the near future and/or • neonates
Details...
11.04.01
Corticosteroids
Betamethasone 0.1% eye drops
Formulary
Betamethasone 0.1% eye ointment
Formulary
Betamethasone 0.1% with Neomycin 0.5% eye drops
Formulary
Short term use only
Dexamethasone 0.1% eye drops (Maxidex®)
Formulary
Dexamethasone 0.1% eye drops (Single dose units)
Formulary
for post corneal implants or OSD
Use the agent with the lowest acquisition cost
Dexamethasone with Antibacterials (Tobradex®)
Formulary
Dexamethasone with Neomycin and Polymyxin B sulphate (Maxitrol®) (Eye Drops/Eye Ointment)
Formulary
Specialist Ophthalmologist Recommendation.
Fluorometholone 0.1% (FML®)
Formulary
Specialist Ophthalmologist Recommendation.
Loteprednol Etabonate 0.5% (Lotemax®)
Formulary
Prednisolone 0.5% eye drops
Formulary
Specialist Ophthalmologist Recommendation .
Prednisolone 1% eye drops (Pred Forte®)
Formulary
Specialist Ophthalmologist Recommendation.
For Anterior Uveitis in A&E-prednisolone acetate 1% as the drug of choice unless the patient has a preference for dexamethasone 0.1%
Hydrocortisone Acetate with Neomycin (Neo-Cortef®)
Non Formulary
Hydrocortisone eye ointment
Non Formulary
Prednisolone 0.5% with Neomycin 0.5% (Predsol-N®)
Non Formulary
Rimexolone (Vexol®)
Non Formulary
Key
Notes
Section Title (top level)
Section Title (sub level)
First Choice item
Non Formulary section
Restricted Drug
Unlicensed
Display tracking information
Link to adult BNF
Link to children's BNF
Link to SPCs
Cytotoxic Drug
Controlled Drug
High Cost Medicine
Cancer Drugs Fund
NHS England
Homecare
CCG
Traffic Light Status Information
Status
Description
Prescribing in children
The APC notes that the informed use of unlicensed medicines or of licensed medicines for unlicensed applications (‘off-label’ use) is often necessary in paediatric practice.
The APC advises GPs to consider specialist prescribing recommendations for Green and Amber medicines that are not subject to ESCAs or RICaDs in combination with the information provided in the BNFC which goes beyond that of marketing authorisations. The BNFC has been designed for rapid reference and the information presented has been carefully selected to aid decisions on prescribing.
Medicines which are suitable for initiation and maintenance prescribing by primary and secondary care clinicians. These medicines should be initiated and prescribed within their licensed indications.
Initiation and maintenance of prescribing by Specialists and transfer to Primary Care prescribing when appropriate, or initiation and maintenance of prescribing in Primary Care following recommendation from a Specialist.
Some amber medicines require agreement with the local (internal) medicines committee prior to initiation; others may require a framework to support safe transfer and maintenance of care such as a RICaD or ESCA. The Formulary will be annotated to reflect these requirements.
Medicines for initiation and maintenance prescribing by Specialists only
Non-formulary medicines- medicines not recommended for routine primary care prescribing.
Positive NICE TA and /or awaiting local clarification on place in therapy ; Please contact your Medicines Optimisation team for more information.
Restricted
